XML 36 R25.htm IDEA: XBRL DOCUMENT v3.19.1
Acquisitions (Tables)
6 Months Ended
Jan. 31, 2019
Net purchase price of HDS

The net purchase price of HDS was determined to be as follows:

 

    Stock Price at Closing   Shares  

Fair

Value

Purchase price:                        
Common Stock at closing   $ .23       1,117,011     $ 253,721  
Common Stock after closing   $ .23       420       95  
Common Stock post reverse stock split   $ .23       4,830,000       1,097,100  
Total purchase price             5,947,431     $ 1,350,916  
Fair Value Assumptions Used in Accounting for Warrants

The key inputs used in the fair value calculations were as follows:

 

    December 1,
2018
  July 31,
2018
Exercise price     2.50       2.50  
Time to expiration     3.14 years       3.47 years  
Risk-free interest rate     3.01 %     2.77 %
Estimated volatility     138.61 %     143.97 %
Dividend     —         —    
Stock price at valuation date   $ 0.9     $ 0.1  
Fair Value Assumptions Used in Accounting for Call Options

The following assumptions were used in estimating the value of the Call Option:

 

    December 1,
2018
  July 31,
2018
Risk-free interest rate     2.52 %     2.44 %
Estimated volatility     164.43 %     129.95 %
Remaining Term     1.13 years       1.47 years  
Stock price at valuation date   $ 0.9043     $ 0.0976  
Purchase price allocated as of acquisition date

The final allocation of the purchase price as of January 31, 2019, is as follows:

 

   

Preliminary Allocation as of December 28,

2017

  Allocation Adjustments   Final Allocation
Intangible assets (licenses)   $ 276,380     $ —       $ 276,380  
Property and equipment     19,879       —         19,879  
Computer software acquired     5,980       —         5,980  
Leasehold Improvements     17,761       —         17,761  
Total assets acquired     320,000       —         320,000  
Consideration:                        
Note Payable     320,000               320,000  
Goodwill   $ —               $ —    
Estimated amortization expense

The preliminary amounts assigned to the identifiable intangible assets, the estimated useful lives, and the estimated amortization expense related to these identifiable intangible assets are as follows:

 

    Preliminary
Fair
Value
  Average
Estimated
Life
Developed Software/Technology   $ 780,000       5  
Referral Base     3,920,000       15  
Non-compete agreements     2,410,000       3  
    $ 7,110,000          
Schedule of Finite-Lived Intangible Assets

The components of the acquired intangible assets were as follows:

 

    Amount   Useful Life (Years)
In-process research and development   $ 3,980,000       —    
Non-compete agreement     790,000       3  
    $ 4,770,000       —    
Supplemental Pro Forma

Unaudited pro forma results of operations for the six months ended January 31, 2018 and 2017 as though the Company acquired HDS, Veneto, Olaregen, Grainland, Empire and Regentys (the “Acquired Companies”) on the first day of each fiscal year are set forth below.

 

   

Six months Ended

January 31

    2018   2017
Revenues   $ 5,839,903     $ 19,407,319  
Cost of revenues     2,810,874       7,622,676  
Gross profit     3,029,029       11,784,643  
Operating expenses     6,406,594       13,592,954  
Operating loss     (3,377,565 )     (1,808,311 )
Other income (expense)     (202,760 )     (123,688 )
Net loss   $ (3,580,325 )     (1,931,999 )
Comprehensive net loss   $ (3,580,325 )   $ (1,931,999 )
Veneto Holdings, L.L.C.  
Summary of Acquisition

The following table summarizes the allocation of the preliminary purchase price as of the Veneto acquisition as of the First Closing and the Second Closing:

 

    “First Closing” completed on
October 3, 2018
  “Second Closing” completed on
November 1, 2018
  Total
Cash and cash equivalents   $ 2,410,150     $ —       $ 2,410,150  
Accounts receivable, net     1,935,078       —         1,935,078  
Inventory, net     1,068,856       —         1,068,856  
Prepaid expenses     95,804       —         95,804  
Property and equipment, net     652,590       —         652,590  
Other receivables     1,014,316       —         1,014,316  
Notes receivable - LT     1,387,763       —         1,387,763  
Other assets, net     25,745       —         25,745  
Intangible assets, net     35,603       7,110,000       7,145,603  
Total assets acquired     8,625,905       7,110,000       15,735,905  
Total current liabilities     2,509,887       —         2,509,887  
Notes payable     —         3,403,948       3,403,948  
Total liabilities assumed     2,509,887       3,403,948       5,913,835  
Net identifiable assets acquired     6,116,018       3,706,052       9,822,070  
Goodwill     8,883,982       16,293,948       25,177,930  
Total consideration transferred   $ 15,000,000     $ 20,000,000     $ 35,000,000  
Regentys  
Summary of Acquisition

The following table summarizes the allocation of the preliminary purchase price as of the Regentys acquisition:

 

   

Preliminary

Allocation as of

January 7,

2019

Cash and cash equivalents   $ 61,857  
Other current assets     13,138  
Property and equipment, net     444  
Accounts payable and accrued liabilities     (1,181,920 )
Notes payable     (639,009 )
Loans from related parties     (16,506 )
Net Tangible Assets   $ (1,761,996 )
Note receivable from Generex     14,345,205  
In-process research & development     3,510,680  
Deferred tax liability     (889,782 )
Redeemable non-controlling interest     (4,073,898 )
Non-controlling interest     (9,870,762 )
Total Fair Value of Assets Acquired     1,259,447  
Consideration:        
Cash paid prior to the time of closing     400,000  
Note receivable from Generex     14,345,205  
Total Purchase Price     14,745,205  
Goodwill   $ 13,485,758  
Olaregen  
Summary of Acquisition

The following table summarizes the allocation of the preliminary purchase price as of the Olaregen acquisition:

 

   

Preliminary

Allocation as of

January 7, 2019

Cash and cash equivalents   $ 608,419  
Prepaid expenses     20,488  
Inventory     408,501  
Other current assets     37,950  
Accounts payable     (216,670 )
Accrued liabilities     (216,694 )
Net Tangible Assets   $ 641,994  
Note receivable from Generex     11,472,663  
In-process research & development     3,980,000  
Non-compete agreement     790,000  
Deferred tax liability     (1,040,173 )
Non-controlling interest     (11,999,559 )
Total assets acquired   $ 3,844,925  
Non-controlling interest     —    
Consideration:        
Cash paid prior to the time of closing     400,000  
Note receivable from Generex     11,472,663  
Goodwill   $ 8,027,738